As of June 2026, Health Canada is advancing workload management measures intended to address human drug submission backlogs, improve review predictability, and support more transparent communication with sponsors. These measures include enhanced communication protocols, expanded reliance approaches, HTA alignment, and operational review efficiencies, while maintaining Health Canada’s review standards for safety, efficacy, and quality.
Health Canada Provides Updates on Human Drug Submission Workload Management
On Tuesday June 23, 2026, at the Pharmaceutical Sciences Group’s (PSG) 9th Annual Day with Health Canada, Karolina Zarichna from Source Nutraceutical, Inc. (SNI) attended discussions on Health Canada’s ongoing initiatives to address human drug submission workload pressures and improve review predictability.
Health Canada discussed the current challenges facing the human drug review program, including increasing submission volumes, greater scientific complexity, and the need to balance timely access to medicines with maintaining review standards for safety, efficacy, and quality.
The overall message focused on collaboration, transparency, and building a more sustainable regulatory review process.
- Why Is Health Canada Modernizing the Drug Review Process?
- Improving Alignment with Health Technology Assessment (HTA)
- How Is Health Canada Reducing Drug Submission Backlogs?
- Expanding International Collaboration and Reliance
- Health Canada’s Workload Management Action Plan
- New Communication Protocol for Drug Submission Reviews
- Long-Term Regulatory Modernization Initiatives
- What Does This Mean for Pharmaceutical Companies?
- Preparing for the Future of Drug Regulation in Canada
Why Is Health Canada Modernizing the Drug Review Process?
Health Canada highlighted that human drug submission workloads have increased significantly over recent years.
Contributing factors include:
- Increasing numbers of new drug submissions and supplements
- Greater complexity of pharmaceutical and biologic products
- Scientific advancements creating more technically complex reviews
- Incomplete submission data packages resulting in additional review cycles
- Resource limitations compared to increasing workload demands
Although these pressures have contributed to submission backlogs, Health Canada highlighted several achievements, including continued efforts to meet review targets, improved operational efficiency, and its recognition as a World Health Organization (WHO) Listed Authority.
Improving Alignment with Health Technology Assessment (HTA)
One area highlighted was Health Canada’s continued work to align regulatory reviews with Health Technology Assessment (HTA) organizations.
Coordinated regulatory and HTA processes are intended to support earlier information sharing and reduce the time between regulatory authorization and reimbursement recommendations.
This approach supports faster access to medicines by improving coordination between regulatory and market access processes.
How Is Health Canada Reducing Drug Submission Backlogs?
Health Canada discussed several measures implemented to improve workload management and review capacity.
These include:
- Additional temporary staffing resources
- Use of contractors and resource reallocation
- Review workflow improvements
- Streamlined review reports
- Increased use of risk-based approaches
- Improved internal processes to reduce administrative burden
The focus is not only on clearing current backlogs but also on creating a sustainable process that prevents future accumulation.
Expanding International Collaboration and Reliance
International collaboration remains a major component of Health Canada’s regulatory modernization strategy.
Health Canada discussed continued involvement in initiatives such as:
- The Access Consortium with Australia, Singapore, Switzerland, and the United Kingdom
- Project Orbis to support consumer access to certain innovative therapies
- Information sharing with international regulatory authorities
- Leveraging foreign review reports where appropriate
Health Canada also discussed ongoing work related to expanded use of reliance approaches with trusted regulatory partners, including the development of frameworks to support more efficient reviews.
Health Canada’s Workload Management Action Plan
Following stakeholder engagement sessions with innovator and generic industry associations, Health Canada developed an action plan focused on three major themes:
1. Improving Communication and Transparency
Feedback collected from industry emphasized the need for greater predictability throughout the review process.
Actions discussed include:
- Broader stakeholder outreach
- Improved availability of information
- Enhanced submission status communication
- Expansion of submission status update tools where applicable
- Optimization of pre-submission and pipeline meetings
Health Canada also discussed exploring the future use of AI-supported tools, such as chat functions, to help respond to routine stakeholder questions and improve access to information.
2. Improving Workload Management
Health Canada discussed several initiatives intended to better manage submission volumes while maintaining predictable review timelines.
These include:
- Developing workload management principles
- Exploring opportunities to accept certain additional information during review where appropriate
- Improving submission completeness tools and checklists
- Supporting industry knowledge-sharing to improve submission quality
- Establishing clearer expectations around extension requests during review
Health Canada emphasized that workload management requires shared responsibility between regulators and sponsors.
3. Reducing the Submission Backlog
Backlog reduction activities discussed included:
- Expanding reliance approaches
- Increasing consistent use of foreign regulatory information during review
- Exploring AI tools to support review processes
- Increasing review capacity through additional resources
These initiatives are intended to address immediate workload pressures while supporting long-term regulatory efficiency.
New Communication Protocol for Drug Submission Reviews
A key update discussed was Health Canada’s development of a communication protocol to improve transparency and predictability. The protocol focuses on clearly defining responsibilities between Health Canada and sponsors.
For certain submissions, Health Canada discussed milestone notifications that may provide earlier communication when a submission is at risk of not meeting its applicable review target.
The goal is to provide sponsors with greater visibility while ensuring reviewer resources remain focused on completing assessments.
Long-Term Regulatory Modernization Initiatives
Health Canada also discussed several longer-term initiatives that may support future efficiencies, including:
- Guidance updates for biosimilar biologic drugs
- Continued implementation of ICH Q12 principles, including greater use of Post-Approval Change Management Protocols (PACMPs)
- Continued advancement of reliance approaches
- Ongoing evaluation of artificial intelligence opportunities within regulatory operations
These initiatives reflect a broader movement toward more adaptable and efficient regulatory systems.
What Does This Mean for Pharmaceutical Companies?
For companies submitting drug applications in Canada, Health Canada’s message reinforces that regulatory efficiency depends on both regulator modernization and sponsor readiness.
Companies should focus on:
- Submitting complete, high-quality applications
- Addressing data expectations early
- Maintaining strong Chemistry, Manufacturing, and Controls (CMC) documentation
- Considering international alignment opportunities
- Engaging Health Canada through appropriate communication channels
- Planning regulatory strategies proactively
While Health Canada continues to implement process improvements, submission quality remains one of the most important factors supporting predictable review timelines.
Preparing for the Future of Drug Regulation in Canada
Health Canada’s current direction reflects a continued focus on transparency, international alignment, operational efficiency, and sustainable workload management.
As regulatory processes continue to evolve, companies should stay informed of new policies, guidance updates, and opportunities to improve submission strategy.
How SNI Supports More Predictable Drug Reviews in Canada
SNI supports pharmaceutical and life sciences companies navigating Canadian drug submissions, Health Canada regulatory strategy, pre-submission planning, CMC documentation readiness, submission lifecycle management, regulatory authority interactions, and post-authorization compliance. Our team helps sponsors prepare stronger submission packages, address potential review risks early, and align Canadian market access planning with Health Canada expectations.
One common challenge for sponsors is uncertainty around submission timing, deficiency risk, and Health Canada communication. SNI helps companies identify gaps before filing, strengthen the regulatory rationale, and prepare more complete submissions to help identify potential review issues earlier and support more efficient regulatory interactions. SNI can help manage your submissions strategically to help identify potential regulatory risks and support more predictable Canadian launch planning.
Book an introductory call using the following form:
The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
